Sequoia-Tata Capital deal for Sai Life comes unstuck?
This article was originally published in Scrip
Executive Summary
Venture capital firm Sequoia's deal with Tata Capital, through which the former was said to be eyeing an exit from the Indian contract research organization (CRO), Sai Life Sciences, may have fallen through, if pharma industry and investment banking experts are to be believed.